GP, K., KM, R., SN, M., & LF, P. (2014). The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use. Dove Medical Press.
Style de citation Chicago (17e éd.)GP, Kaufman, Ristow KM, Markovic SN, et Porrata LF. The Absolute Lymphocyte/monocyte Ratio Recovery During ABVD Treatment Cycles Is Not Significantly Impacted by the Use of Myeloid Growth Factors and Predicts Clinical Outcomes in Classical Hodgkin Lymphoma Regardless of Their Use. Dove Medical Press, 2014.
Style de citation MLA (8e éd.)GP, Kaufman, et al. The Absolute Lymphocyte/monocyte Ratio Recovery During ABVD Treatment Cycles Is Not Significantly Impacted by the Use of Myeloid Growth Factors and Predicts Clinical Outcomes in Classical Hodgkin Lymphoma Regardless of Their Use. Dove Medical Press, 2014.